Loading clinical trials...

COMPLETEDNA

Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)

An Assessor-blinded, Randomized, 20-week, Parallel-group, Superiority Study to Compare the Efficacy of Transdiagnostic Cognitive Behavioral Therapy Versus Waiting-list in Depressive and Anxiety Symptoms of Depressive and Anxiety Disorders

NCT02003261•National Center of Neurology and Psychiatry, Japan

View on ClinicalTrials.gov

Summary

This study is to examine the superiority of the combined treatments of transdiagnostic cognitive-behavior therapy (Unified Protocol; UP) and Treatment-As-Usual in comparison with the waiting-list with Treatment-As-Usual in the reduction of depressive and anxiety symptoms among depressive and anxiety disorders.

Detailed Description

Participants with depressive or anxiety disorders will be randomized to either Unified Protocol with Treatment-As-Usual or Wail-list with Treatment-As-Usual. Intervention period will be 20-week and the follow-up period will be 43 week from registration.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•DSM-IV diagnosis of Major Depressive Disorder, Dysthymia, Depressive Disorder Not Otherwise Specified, Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Agoraphobia Without History of Panic Disorder, Social Phobia(Social Anxiety Disorder), Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder Not Otherwise Specified assessed by SCID.
•Depressive and anxiety symptoms is mild or more severe (GRID-HAMD \>= 8).
•Ages 20 years or older, and 65 years or younger at screening.
•Subjects who give full consent in the participation of the study.

Exclusion Criteria

•No alcohol or substance use disorder in 6 months prior to the screening assessed by SCID
•No current manic episode or current schizophrenia and other psychotic disorders at baseline assessed by SCID
•No serious suicidal ideation at baseline (GRID-HAMD Item3 severity is 3 or higher.)
•No life-threatening, severe or unstable physical disorders or major cognitive deficits at baseline.
•Evidence of unable to participate half or more of the intervention phase.
•No structured psychotherapy during at baseline.
•Other relevant reason decided by the investigators.

Locations (1)

National Center of Neurology and Psychiatry

Kodaira, Tokyo, Japan

Key Dates

Start Date

January 31, 2014

Primary Completion Date

November 2, 2018

Completion Date

April 5, 2019

Last Updated

August 21, 2019

Enrollment

104

ACTUAL participants

Conditions

Anxiety DisordersDepressive Disorders

Interventions

Unified Protocol with Treatment As Usual

BEHAVIORAL

Treatment As Usual

OTHER

In Vivo Exposure vs. Videochat-Based Vicarious Exposure

NCT07432945

AnxietyAnxiety Disorders

View study

RECRUITINGNA

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

NCT06661460

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)Specific Phobia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 21, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)

Inclusion Criteria

Exclusion Criteria

In Vivo Exposure vs. Videochat-Based Vicarious Exposure

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention

Investigating Neural Response Variability as a Single-patient Predictor of Successful CBT in Clinical Psychiatry

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation